Men's Health

Alphabetical News Index

Cialis For Prostatic

Hyperplasia

Delay of Treatment For

Low Risk Prostate Cancer

Endorsed

European Men’s Health

Need Improvement

Heart Health Risk of

Prostate Cancer Treatment

Men’s Health

Heart health risk of prostate cancer treatment being ignored, warn specialists

[Cardiovascular risk in androgen suppression: underappreciated, under-researched, and unresolved Online First 2011; doi 10.1136/heartjnl-2011-300893]

Heart disease and stroke are emerging complications of treating prostate cancer with drugs to suppress testosterone production, yet standard management of the disease is ignoring this risk, warn specialists in a viewpoint published online in Heart.

Drugs to suppress production of the male hormone testosterone, known as androgen suppression therapy (AST), are a mainstay of treatment for advanced prostate cancer, write the authors. And there is good evidence to show that they work well.

Panel Endorses Active monitoring And Delay Of Treatment For Low-Risk Prostate Cancer

Urges further research to clarify management strategies

An independent panel convened this week by the National Institutes of Health has concluded that many men with localized, low-risk prostate cancer should be closely monitored, permitting treatment to be delayed until warranted by disease progression. However, monitoring strategies-such as active surveillance-have not been uniformly studied and available data do not yet point to clear follow-up protocols. The panel recommended standardizing definitions and conducting additional studies to clarify which monitoring strategies are most likely to optimize patient outcomes.

Action needed to improve men’s health in Europe

Analysis: Europe’s men need their own health strategy

Editorial: The state of men’s health in Europe

Policies aimed specifically at men are urgently needed to improve the health of Europe’s men, say experts on bmj.com today.

Action is needed throughout the life course and in every setting say Professor Alan White at Leeds Metropolitan University and colleagues whose recent report, The State of Men’s Health in Europe, shows marked differences in health outcomes between men, which are strongly related to their biology, culture, and socioeconomic realities.

FDA approves Cialis to treat benign prostatic hyperplasia

The U.S. Food and Drug Administration today approved Cialis (tadalafil) to treat the signs and symptoms of benign prostatic hyperplasia (BPH), a condition in which the prostate gland becomes enlarged, and for the treatment of BPH and erectile dysfunction (ED), when the conditions occur simultaneously. Cialis was approved in 2003 for the treatment of ED.

Common symptoms of BPH include difficulty in starting urination and a weak urine stream; a sudden urge to urinate; and more frequent urination including at night.

Home | Contact | Disclaimer | Tour | Links Exchange

TeleMed International HQ, Inc. | Medical Standard Systems Corporation

Disclaimer: The opinions expressed by governmental institutions, authorities, scholars, academicians, researchers, educational institutions, pharmaceutical organizations, advertisers, individuals, websites, blogs and links featured at HcVN are their own. They may not reflect or parallel our own thoughts and should not be taken as an endorsement. With regards to your health related issues traditional or integrated, please consult your physicians.